Initial management and survival of patients with primary metastatic bladder cancer before the immunotherapy era: a population-based study from Norway
Conclusion: Before immunotherapy, more than 50% of patients with primary mBC did not receive any initial anti-cancer therapy and had a poor survival. Patients treated with chemotherapy had inferior median OS compared to those treated with comparable systemic strategies in contemporary trials. Our results provide a basis for future research on treatment and survival after the introduction of immunotherapy for mBC, aiming to improve the care and outcome of patients with mBC.PMID:37953521 | DOI:10.2340/sju.v58.5923 (Source: Scandinavian Journal of Urology)
Source: Scandinavian Journal of Urology - November 13, 2023 Category: Urology & Nephrology Authors: Christina Tanem M øller Gunnar Tafjord Augun Blindheim Viktor Berge Sophie Foss å Bettina Kulle Andreassen Source Type: research
Uptake of doublet therapy for de novo metastatic castration sensitive prostate cancer: a population-based drug utilisation study in Sweden
CONCLUSIONS: Slightly more than half of men diagnosed with de novo metastatic castration-sensitive prostate cancer and a life expectancy of at least 3 years received additions to standard ADT as recommended by national guidelines in 2019-2022 in Sweden. There was a 2-fold increase in use of these treatments during the study period; however, efforts to further increase adherence to guidelines are warranted.PMID:37953522 | DOI:10.2340/sju.v58.9572 (Source: Scandinavian Journal of Urology)
Source: Scandinavian Journal of Urology - November 13, 2023 Category: Urology & Nephrology Authors: Rolf Gedeborg Fredrik Sandin Camilla Thellenberg-Karlsson Johan Styrke Ingela Franck Lissbrant Hans Garmo P är Stattin Source Type: research
Initial management and survival of patients with primary metastatic bladder cancer before the immunotherapy era: a population-based study from Norway
Conclusion: Before immunotherapy, more than 50% of patients with primary mBC did not receive any initial anti-cancer therapy and had a poor survival. Patients treated with chemotherapy had inferior median OS compared to those treated with comparable systemic strategies in contemporary trials. Our results provide a basis for future research on treatment and survival after the introduction of immunotherapy for mBC, aiming to improve the care and outcome of patients with mBC.PMID:37953521 | DOI:10.2340/sju.v58.5923 (Source: Scandinavian Journal of Urology)
Source: Scandinavian Journal of Urology - November 13, 2023 Category: Urology & Nephrology Authors: Christina Tanem M øller Gunnar Tafjord Augun Blindheim Viktor Berge Sophie Foss å Bettina Kulle Andreassen Source Type: research
Uptake of doublet therapy for de novo metastatic castration sensitive prostate cancer: a population-based drug utilisation study in Sweden
CONCLUSIONS: Slightly more than half of men diagnosed with de novo metastatic castration-sensitive prostate cancer and a life expectancy of at least 3 years received additions to standard ADT as recommended by national guidelines in 2019-2022 in Sweden. There was a 2-fold increase in use of these treatments during the study period; however, efforts to further increase adherence to guidelines are warranted.PMID:37953522 | DOI:10.2340/sju.v58.9572 (Source: Scandinavian Journal of Urology)
Source: Scandinavian Journal of Urology - November 13, 2023 Category: Urology & Nephrology Authors: Rolf Gedeborg Fredrik Sandin Camilla Thellenberg-Karlsson Johan Styrke Ingela Franck Lissbrant Hans Garmo P är Stattin Source Type: research
Initial management and survival of patients with primary metastatic bladder cancer before the immunotherapy era: a population-based study from Norway
Conclusion: Before immunotherapy, more than 50% of patients with primary mBC did not receive any initial anti-cancer therapy and had a poor survival. Patients treated with chemotherapy had inferior median OS compared to those treated with comparable systemic strategies in contemporary trials. Our results provide a basis for future research on treatment and survival after the introduction of immunotherapy for mBC, aiming to improve the care and outcome of patients with mBC.PMID:37953521 | DOI:10.2340/sju.v58.5923 (Source: Scandinavian Journal of Urology)
Source: Scandinavian Journal of Urology - November 13, 2023 Category: Urology & Nephrology Authors: Christina Tanem M øller Gunnar Tafjord Augun Blindheim Viktor Berge Sophie Foss å Bettina Kulle Andreassen Source Type: research
Uptake of doublet therapy for de novo metastatic castration sensitive prostate cancer: a population-based drug utilisation study in Sweden
CONCLUSIONS: Slightly more than half of men diagnosed with de novo metastatic castration-sensitive prostate cancer and a life expectancy of at least 3 years received additions to standard ADT as recommended by national guidelines in 2019-2022 in Sweden. There was a 2-fold increase in use of these treatments during the study period; however, efforts to further increase adherence to guidelines are warranted.PMID:37953522 | DOI:10.2340/sju.v58.9572 (Source: Scandinavian Journal of Urology)
Source: Scandinavian Journal of Urology - November 13, 2023 Category: Urology & Nephrology Authors: Rolf Gedeborg Fredrik Sandin Camilla Thellenberg-Karlsson Johan Styrke Ingela Franck Lissbrant Hans Garmo P är Stattin Source Type: research
Long-term efficacy of selective arterial embolisation of renal angiomyolipoma
CONCLUSIONS: Being a well-tolerated treatment with few complications, selective arterial embolisation renders a pronounced size-reduction in most patients with AML, and kidney function is preserved. Regrowth is common, and a radiological follow-up is necessary. Tuberous sclerosis is a risk factor for the need of reintervention.PMID:37909895 | DOI:10.2340/sju.v58.12318 (Source: Scandinavian Journal of Urology)
Source: Scandinavian Journal of Urology - November 1, 2023 Category: Urology & Nephrology Authors: Jesper Sw ärd Karl Bohlin Olof Henrikson Sven Lundstam Ralph Peeker Anna Grenabo Bergdahl Source Type: research
